Details for New Drug Application (NDA): 207477
✉ Email this page to a colleague
NDA 207477 describes SOLIFENACIN SUCCINATE, which is a drug marketed by Accord Hlthcare, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma, Austarpharma, Breckenridge, Chartwell Rx, Cipla, Glenmark Speclt, Lannett Co Inc, Macleods Pharms Ltd, MSN, Qilu, Rising, Sciegen Pharms Inc, Strides Pharma, Sunshine, Teva Pharms Usa, Unichem, Watson Labs Inc, and Zydus Pharms, and is included in twenty-four NDAs. It is available from twenty-six suppliers. Additional details are available on the SOLIFENACIN SUCCINATE profile page.
The generic ingredient in SOLIFENACIN SUCCINATE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
The generic ingredient in SOLIFENACIN SUCCINATE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for 207477
| Tradename: | SOLIFENACIN SUCCINATE |
| Applicant: | Accord Hlthcare |
| Ingredient: | solifenacin succinate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 207477
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Jan 4, 2022 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Jan 4, 2022 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
